表皮生长因子受体突变指导的肺癌治疗：我们现在在哪里？

Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?

机构信息

Vanderbilt-Ingram Cancer Center, Department of Medicine/Division of Hematology-Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

出版信息

Thorac Cancer. 2011 Feb;2(1):1-6. doi: 10.1111/j.1759-7714.2010.00035.x.

DOI:10.1111/j.1759-7714.2010.00035.x

PMID:27755839

Abstract

Epidermal growth factor receptor (EGFR) kinase domain mutations (from exon 18 to 21) alter the efficacy of the EGFR tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung cancer patients with drug-sensitive EGFR mutations initially respond, but acquire resistance after approximately one year of tyrosine kinase inhibitor treatment. This review summarizes EGFR gene mutation profiles for East Asian non-small-cell lung cancer patients according to recent publications. Strategies for the treatment of acquired resistance mediated by EGFR T790M are also reviewed.

摘要

表皮生长因子受体（EGFR）激酶结构域突变（外显子 18 至 21）改变了 EGFR 酪氨酸激酶抑制剂吉非替尼（易瑞沙）和厄洛替尼（特罗凯）的疗效。具有药物敏感 EGFR 突变的肺癌患者最初有反应，但在接受酪氨酸激酶抑制剂治疗约一年后会产生耐药性。本综述根据最近的出版物总结了东亚非小细胞肺癌患者的 EGFR 基因突变谱。还回顾了针对 EGFR T790M 介导的获得性耐药的治疗策略。